• Bukwang Pharm signed an Oct. 15, 2026, agreement with Samsung Medical Center and BlueSignum to co-develop schizophrenia digital therapeutic Affectus.
• The partnership, announced Oct. 22, covers clinical development, product enhancement and regulatory approvals through commercialization.
• Affectus aims to improve social cognition in schizophrenia patients; an exploratory clinical trial is underway at Samsung Medical Center.
• The collaboration combines pharmaceutical commercialization expertise with the hospital’s clinical research capabilities and BlueSignum’s digital product development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bukwang Pharm. Co. Ltd. published the original content used to generate this news brief on October 22, 2026, and is solely responsible for the information contained therein.